Form 4 Filing for Dyne Therapeutics, Inc. by Kersten Dirk

On April 21 and 22, 2026, Kersten Dirk, a director at Dyne Therapeutics, Inc., reported the sale of 8,300 and 2,652 shares of common stock, respectively. These transactions were executed under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices, with the first batch selling between $20.00 and $20.08, and the second batch selling between $20.00 and $20.02. The shares are held indirectly through ForDyne, with Mr. Dirk having a pecuniary interest and potentially shared voting/dispositive power through his roles in various Forbion entities. Following these transactions, the post-transaction shares owned by ForDyne were 4,199,225 and 4,196,573, respectively.